

## DAFTAR PUSTAKA

- Agrahari, Vibhuti, Mandal, A., Agrahari, Vivek, Trinh, H.M., Joseph, M., Ray, A., Hadji, H., Mitra, R., Pal, D. & Mitra, A.K. (2016) "A comprehensive insight on ocular pharmacokinetics," *Drug Delivery and Translational Research*, 6(6), pp. 735–754.
- Amoaku, W., Blakeney, S., Freeman, M., Gale, R., Johnston, R., Kelly, S.P., McLaughlan, B., Sahu, D., Varma, D. & group, the A. on A.M.D. (2012) "Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care," *Eye*, 26(1), pp. S2–S21.
- Anon (2019) *Age-Related Macular Degeneration (AMD) Data and Statistics*. [Online]
- Arevalo, J.F., Liu, T.Y.A. & Pan-American Collaborative Retina Study Group (PACORES) (2018) "Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture.," *Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)*, 7(1), .
- Bernard Rosner (2010) *Fundamentals of Biostatistics*. 7th edition. Boston: BROOKS/COLE CENGAGE Learning.
- Bourne, R.R.A., Steinmetz, J.D., Saylan, M., Mersha, A.M., Weldemariam, A.H., Wondmeneh, T.G., Sreeramareddy, C.T., Pinheiro, M., Yaseri, M., Yu, C., Zastrozhin, M.S., Zastrozhina, A., Zhang, Z.J., Zimsen, S.R.M., Yonemoto, N., Tsegaye, G.W., Vu, G.T., Vongpradith, A., Renzaho, A.M.N., et al. (2021) "Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study," *The Lancet Global Health*, 9(2), pp. e144–e160.
- Decroos, F.C. & Haller, J.A. (2013) "Risk factors for age-related macular degeneration and choroidal neovascularization," in *Age-Related Macular Degeneration*. [Online]. pp. 54–56.
- Detaram, H.D., Joachim, N., Liew, G., Vu, K. van, Burlutsky, G., Mitchell, P. & Gopinath, B. (2020) "Smoking and treatment outcomes of neovascular age-related macular degeneration over 12 months," *British Journal of Ophthalmology*, 104(7), pp. 893–898.
- Falavarjani, K.G. & Nguyen, Q.D. (2013) "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature," *Eye (London, England)*, 27(7), pp. 787–794.

- Fogli, S., del Re, M., Rofi, E., Posarelli, C., Figus, M. & Danesi, R. (2018) "Clinical pharmacology of intravitreal anti-VEGF drugs," *Eye*, 32(6), .
- Foss, A., Haydock, R., Childs, M., Duley, L.M., Empeslidis, T., Dhar-Munshi, S., Montgomery, A.A., Ogollah, R., Ozolins, M., Tesha, P. & Mitchell, E. (2020) "TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands," *BMJ Open Ophthalmology*, 5(1), .
- Frenkel, M.P.C. (2010) "Effect of Prophylactic Intraocular Pressure-Lowering Medication on Intraocular Pressure Spikes After Intravitreal Injections," *Archives of Ophthalmology*, 128(12), p. 1523.
- Fung, A.E., Rosenfeld, P.J. & Reichel, E. (2006) "The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide," *British Journal of Ophthalmology*, 90(11), .
- Garcia, J., Hurwitz, H.I., Sandler, A.B., Miles, D., Coleman, R.L., Deurloo, R. & Chinot, O.L. (2020) "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook," *Cancer Treatment Reviews*, 86.
- García-Layana, A., Cabrera-López, F., García-Arumí, J., Arias-Barquet, L. & Ruiz-Moreno, J.M. (2017) "Early and intermediate age-related macular degeneration: update and clinical review," *Clinical interventions in aging*, 12pp. 1579–1587.
- Gehrs, K.M., Anderson, D.H., Johnson, L. v & Hageman, G.S. (2006) "Age-related macular degeneration--emerging pathogenetic and therapeutic concepts," *Annals of medicine*, 38(7), pp. 450–471.
- Heesterbeek, T.J., Lechanteur, Y.T.E., Lorés-Motta, L., Schick, T., Daha, M.R., Altay, L., Liakopoulos, S., Smailhodzic, D., den Hollander, A.I., Hoyng, C.B., de Jong, E.K. & Klevering, B.J. (2020) "Complement Activation Levels Are Related to Disease Stage in AMD," *Investigative ophthalmology & visual science*, 61(3), p. 18.
- Kaiser (2007) "Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration," *Core Evidence*,
- Kang, S.J. & Grossniklaus, H.E. (2013) "Histopathology of age-related macular degeneration," in Lim (ed.) *Age-Related Macular Degeneration*. 3rd edition [Online]. Boca Raton: CRC Press.
- Keane, P.A., Patel, P.J., Liakopoulos, S., Heussen, F.M., Sadda, S.R. & Tufail, A. (2012) "Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography," *Survey of Ophthalmology*, 57(5), pp. 389–414.

- Khandhadia, S., Cipriani, V., Yates, J.R.W. & Lotery, A.J. (2012) “Age-related macular degeneration and the complement system,” *Immunobiology*, 217(2), .
- Kim, Judy E., Mantravadi, A. v., Hur, E.Y. & Covert, D.J. (2008) “Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents,” *American Journal of Ophthalmology*, 146(6), .
- Kim, Judy E, Mantravadi, A. v, Hur, E.Y. & Covert, D.J. (2008) “Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents,” *American Journal of Ophthalmology*, 146(6), pp. 930-934.e1.
- Lamprakakis, I., Todorova, M.G., Grüb, M. & Schlote, T. (2017) “The Impact of Multiple Intravitreal Anti-VEGF Injections on Intraocular Pressure,” *Klinische Monatsblätter für Augenheilkunde*, 235(11), pp. 1278–1284.
- Lim, J.I. (2013) “Neovascular age-related macular degeneration,” in Jennifer I Lim (ed.) *Age-Related Macular Degeneration*. 3rd edition [Online]. Boca Raton: CRC Press.
- van Lookeren Campagne, M., LeCouter, J., Yaspan, B.L. & Ye, W. (2014) “Mechanisms of age-related macular degeneration and therapeutic opportunities,” *The Journal of Pathology*, 232(2), pp. 151–164.
- Maruyama-Inoue, M., Inoue, T., Mohamed, S., Kitajima, Y., Ikeda, S., Ito, A. & Kadonosono, K. (2021) “Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration,” *Scientific Reports*, 11(1), .
- Mazzoni, F., Safa, H. & Finnemann, S.C. (2014) “Understanding photoreceptor outer segment phagocytosis: use and utility of RPE cells in culture,” *Experimental eye research*, 126pp. 51–60.
- Mitchell, P., Liew, G., Gopinath, B. & Wong, T.Y. (2018) “Age-related macular degeneration.” *The Lancet* 392 (10153) p.pp. 1147–1159.
- Mokwa, N.F., Ristau, T., Keane, P.A., Kirchhof, B., Sadda, S.R. & Liakopoulos, S. (2013) “Grading of Age-Related Macular Degeneration: Comparison between Color Fundus Photography, Fluorescein Angiography, and Spectral Domain Optical Coherence Tomography” Andreas W A Weinberger (ed.), *Journal of Ophthalmology*, 2013p. 385915.
- Mousavi, M. & Armstrong, R.A. (2013) “Genetic risk factors and age-related macular degeneration (AMD),” *Journal of Optometry*, 6(4), pp. 176–184.

- Petri, A.-S., Boysen, K., Cehofski, L.J., van Dijk, E.H.C., Dysli, C., Fuchs, J., Mastropasqua, R. & Subhi, Y. (2020) "Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach," *Ophthalmology and Therapy*, 9(1), .
- PEYMAN, G.A., LAD, E.M. & MOSHFEGHI, D.M. (2009) "INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS," *Retina*, 29(7), .
- Ricci, F., Bandello, F., Navarra, P., Staurenghi, G., Stumpp, M. & Zarbin, M. (2020) "Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches," *International Journal of Molecular Sciences*, 21(21), .
- Singh, R.S.J. & Kim, J.E. (2012) "Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents," *Drugs & Aging*, 29(12), .
- Solomon, S.D., Lindsley, K., Vedula, S.S., Krzystolik, M.G. & Hawkins, B.S. (2019) "Anti-vascular endothelial growth factor for neovascular age-related macular degeneration," *Cochrane Database of Systematic Reviews*, 2019(3), .
- Storey, P.P., Patel, D. & Garg, S. (2020) "Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents," *Canadian Journal of Ophthalmology*, 55(4), .
- de Vries, Victor.A., Bassil, F.L. & Ramdas, Wishal.D. (2020) "The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis," *Scientific Reports*, 10(1), p. 13248.
- Wilson, M.R. & Singh, K. (2009) "Intraocular Pressure: Does it Measure Up?," *The Open Ophthalmology Journal*, 3(2), .
- Wong, W.L., Su, X., Li, X., Cheung, C.M.G., Klein, R., Cheng, C.Y. & Wong, T.Y. (2014) "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis," *The Lancet Global Health*, 2(2), .
- Zhang, Z.-Y., Bao, X.-L., Cong, Y.-Y., Fan, B. & Li, G.-Y. (2020) "Autophagy in Age-Related Macular Degeneration: A Regulatory Mechanism of Oxidative Stress," *Oxidative medicine and cellular longevity*, 2020p. 2896036.